Predictive
Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”)
to personalized medicine and drug discovery, this morning announced that its
Helomics subsidiary has begun to sequence tumor cases from its collaboration
with the UPMC Magee Women’s Hospital (http://ibn.fm/b9BBo). According to the update, the Helomics
and UPMC Magee partnership focuses on analyzing the genomic and drug response
profiles of women with ovarian cancer to build AI-driven predictive models’
terms of therapy response. A key benchmark in Predictive Oncology’s Cancer
Quest 2020 project, the collaboration takes a retrospective look at around 400
ovarian cancer cases that Helomics profiled for drug response, for which UMPC
Magee has outcome data. “These retrospective ovarian cancer cases were profiled
by Helomics as early as 2010; hence, we have 10 years’ worth of drug treatment
data, survival and other outcome measures we are gathering from Magee’s
clinical databases,” Helomics CTO Dr. Mark Collins stated in the news release.
“We are now sequencing these cases, looking at both the tumor mutations
(genome) as well as tumor gene expression (transcriptome) to build a
comprehensive multi-omic picture of the tumor. We are also using deep learning
on histopathology images of the tumor tissue (tissue-omics) to add an
additional dimension to this multi-omic profile. We believe the combination of
the rich multi-omic profile of the tumor and clinical outcome data will allow
us to build an AI-driven model of ovarian cancer capable of predicting the
tumor drug response and patient outcome (prognosis).”
To view the full press release, visit http://ibn.fm/Okaan
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on
applying artificial intelligence to personalized medicine and drug discovery.
The company applies smart tumor profiling and its AI platform to extensive
genomic and biomarker patient data sets to predict clinical outcomes and, most
importantly, improve patient outcomes for cancer patients of today and
tomorrow. Predictive Oncology currently has approximately 150,000 clinically
validated cases on its molecular information platform, with more than 38,000
specific to ovarian cancer. The company’s data is highly differentiated, having
both drug-response data and access to historical outcome data from patients.
Predictive Oncology intends to generate additional sequence data from these
tumor samples to deliver on the clear unmet market need across the
pharmaceutical industry for a multi-omic approach to new drug development. For
more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
